MannKind reported $-19.03M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Adma Biologics USD 37.82M 7.51M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Halozyme Therapeutics USD 247.05M 17.14M Sep/2026
Insmed USD -13.24M 150.32M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
MacroGenics USD 19.52M 56.29M Jun/2026
MannKind USD -19.03M 2.41M Jun/2026
Merck USD 5.07B 6.4B Sep/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Novavax USD 17.53M 219.91M Dec/2025
Novo Nordisk DKK 3.26B 45.29B Jun/2026
Pfizer USD 3.24B 3.49B Sep/2026
Sanofi EUR 3.02B 2.68B Sep/2026
Xencor USD -21.73M 107.19M Jun/2026